2022
The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial
Zarrabi M, Akbari M, Amanat M, Majmaa A, Moaiedi A, Montazerlotfelahi H, Nouri M, Hamidieh A, Badv R, Karimi H, Rabbani A, Mohebbi A, Rahimi-Dehgolan S, Rahimi R, Dehghan E, Vosough M, Abroun S, Shamsabadi F, Tavasoli A, Alizadeh H, Pak N, Zamani G, Mohammadi M, Javadzadeh M, Ghofrani M, Hassanpour S, Heidari M, Taghdiri M, Mohseni M, Noparast Z, Masoomi S, Goudarzi M, Mohamadpour M, Shodjaee R, Samimi S, Mohammad M, Gholami M, Vafaei N, Koochakzadeh L, Valizadeh A, Malamiri R, Ashrafi M. The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. BMC Neurology 2022, 22: 123. PMID: 35351020, PMCID: PMC8966246, DOI: 10.1186/s12883-022-02636-y.Peer-Reviewed Original ResearchConceptsUmbilical cord blood mononuclear cellsCord blood mononuclear cellsSpastic cerebral palsyBlood mononuclear cellsCerebral palsyHuman leukocyte antigenPosterior thalamic radiationUCB-MNCAdverse eventsFractional anisotropyMononuclear cellsCorticospinal tractWhite matter structuresMean changeDouble-blind sham-controlled clinical trialControl groupMean GMFM-66 scoresGross Motor Function MeasureSham-controlled clinical trialExperimental groupCommon adverse eventsDouble-blind studyMotor Function MeasureGMFM-66 scoresTrial registrationThe studyDisease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
Valizadeh A, Fattahi M, Sadeghi M, Torbati M, Sahraian M, Azimi A. Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis. CNS Neuroscience & Therapeutics 2022, 28: 648-657. PMID: 35218155, PMCID: PMC8981477, DOI: 10.1111/cns.13815.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesCertainty of evidenceVolumes of T1Hypointense lesionsMultiple sclerosis patientsRisk of biasRoB 2 toolT1-hypointense lesionsRandom-effects modelEffects of FDANumber of lesionsAdult patientsSclerosis patientsMultiple sclerosisComparator groupPrognostic markerObjective markersSystematic reviewLesionsMean differenceMean volumePatientsRelevant studiesHypointenseTherapy
2021
Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis
Valizadeh A, Moassefi M, Barati E, Sahraian M, Aghajani F, Fattahi M. Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis. CNS Neuroscience & Therapeutics 2021, 27: 1268-1280. PMID: 34605190, PMCID: PMC8504532, DOI: 10.1111/cns.13734.Peer-Reviewed Original ResearchConceptsMean volumeCerebral magnetic resonance imagingPrognosis Studies toolMultiple sclerosis patientsRisk of biasT1-hypointense lesionsRandom-effects modelMagnetic resonance imagingWeb of ScienceClinical disabilityAdult patientsCerebral MRIEDSS scoreSclerosis patientsMultiple sclerosisDisability levelHypointense lesionsSystematic reviewResonance imagingPatientsRelevant studiesStudy toolCorrelation coefficientT1EDSSA placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury.
Shimia M, Iranmehr A, Valizadeh A, Mirzaei F, Namvar M, Rafiei E, Rahimi A, Khadivi A, Aeinfar K. A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury. Journal Of Neurosurgical Sciences 2021, 67: 598-604. PMID: 34114429, DOI: 10.23736/s0390-5616.21.05266-8.Peer-Reviewed Original ResearchConceptsGlasgow Outcome ScaleDisability Rating ScaleTraumatic brain injurySevere TBI patientsAmantadine hydrochlorideTBI patientsBrain injuryFunctional improvementClinical trialsSevere acute traumatic brain injuryAcute traumatic brain injuryMean Glasgow Outcome ScaleSevere traumatic brain injuryFunctional ability improvementEffect of amantadineDopaminergic neurotransmitter systemWeeks of trialAmantadine groupPharmacologic optionsDopamine agonistsOutcome ScaleNeurotransmitter systemsOutcome measurementsPatientsRating Scale
2019
Potential role of regulatory B cells in immunological diseases
Valizadeh A, Sanaei R, Rezaei N, Azizi G, Fekrvand S, Aghamohammadi A, Yazdani R. Potential role of regulatory B cells in immunological diseases. Immunology Letters 2019, 215: 48-59. PMID: 31442542, DOI: 10.1016/j.imlet.2019.08.004.Peer-Reviewed Original ResearchConceptsRegulatory B cellsB cellsImmune systemChronic infectious diseasePotential therapeutic strategyMechanism of actionCytokine productionImmunomodulatory effectsPrimary immunodeficiencyTherapeutic strategiesImmunological diseasesTherapeutic effortsInfectious diseasesExact phenotypeDiseaseFindings of humanPotential roleBregsDiverse diseasesCellsCellular interactionsOngoing investigationAutoimmunityAllergyMalignancy